Atopic Dermatitis Ad Epidemiology Forecast

DelveInsight's 'Atopic Dermatitis (AD) - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Atopic Dermatitis (AD) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.


Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan


Study Period: 2017-2030


Atopic Dermatitis (AD) Understanding

The DelveInsight Atopic Dermatitis (AD) epidemiology report gives a thorough understanding of the Atopic Dermatitis (AD) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Atopic Dermatitis (AD) in the US, Europe, and Japan. The report covers the detailed information of the Atopic Dermatitis (AD) epidemiology scenario in seven major countries (US, EU5, and Japan).


Atopic Dermatitis (AD) Epidemiology Perspective by DelveInsight

The Atopic Dermatitis (AD) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Atopic Dermatitis (AD) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Atopic Dermatitis (AD) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.


Atopic Dermatitis (AD) Detailed Epidemiology Segmentation

The Atopic Dermatitis (AD) epidemiology covered in the report provides historical as well as forecasted Atopic Dermatitis (AD) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight Atopic Dermatitis (AD) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.


Scope of the Report

  • The Atopic Dermatitis (AD) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Atopic Dermatitis (AD) Epidemiology Report and Model provide an overview of the risk factors and global trends of Atopic Dermatitis (AD) in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Atopic Dermatitis (AD) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Atopic Dermatitis (AD)
  • The report provides the segmentation of the Atopic Dermatitis (AD) epidemiology


Report Highlights

  • 11-Year Forecast of Atopic Dermatitis (AD) epidemiology
  • 7MM Coverage
  • Total Cases of Atopic Dermatitis (AD)
  • Total Cases of Atopic Dermatitis (AD) according to segmentation
  • Diagnosed cases of Atopic Dermatitis (AD)


KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.


Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Atopic Dermatitis (AD)?
  • What are the key findings pertaining to the Atopic Dermatitis (AD) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Atopic Dermatitis (AD) across the 7MM during the forecast period (2017-2030)?
  •  Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Atopic Dermatitis (AD)?
  • What are the currently available treatments of Atopic Dermatitis (AD)?


Reasons to buy

  • The Atopic Dermatitis (AD) Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Atopic Dermatitis (AD) market
  • Quantify patient populations in the global Atopic Dermatitis (AD) market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Atopic Dermatitis (AD) therapeutics in each of the markets covered
  • Understand the magnitude of Atopic Dermatitis (AD) population by its epidemiology
  • The Atopic Dermatitis (AD) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources


Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights 

2. Executive Summary of Atopic Dermatitis (AD)

3. Atopic Dermatitis (AD): Disease Background and Overview

3.1. Introduction

3.2. Sign and Symptoms

3.3. Pathophysiology

3.4. Risk Factors

3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

5.1. Epidemiology Key Findings

5.2. Assumptions and Rationale: 7MM

5.3. Epidemiology Scenario: 7MM

5.3.1. Atopic Dermatitis (AD) Epidemiology Scenario in the 7MM (2017- 2030)

5.4. United States Epidemiology

5.4.1. Atopic Dermatitis (AD) Epidemiology Scenario in the United States (2017- 2030)

5.5. EU-5 Country-wise Epidemiology

5.5.1. Germany Epidemiology

5.5.1.1. Atopic Dermatitis (AD) Epidemiology Scenario in Germany (2017- 2030)

5.5.2. France Epidemiology

5.5.2.1. Atopic Dermatitis (AD) Epidemiology Scenario in France (2017- 2030)

5.5.3. Italy Epidemiology

5.5.3.1. Atopic Dermatitis (AD) Epidemiology Scenario in Italy (2017- 2030)

5.5.4. Spain Epidemiology

5.5.4.1. Atopic Dermatitis (AD) Epidemiology Scenario in Spain (2017- 2030)

5.5.5. United Kingdom Epidemiology

5.5.5.1. Atopic Dermatitis (AD) Epidemiology Scenario in the United Kingdom (2017-2030)

5.6. Japan Epidemiology

5.6.1. Atopic Dermatitis (AD) Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

6.1. Atopic Dermatitis (AD) Treatment and Management

6.2. Atopic Dermatitis (AD) Treatment Algorithm

7. KOL Views

8. Unmet Needs

9.  Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

*The table of contents is not exhaustive; will be provided in the final report

Table 1  Atopic Dermatitis (AD) Epidemiology in 7MM (2017-2030)

Table 2 Atopic Dermatitis (AD) Diagnosed and Treatable Cases in 7MM (2017-2030)

Table 3 Atopic Dermatitis (AD) Epidemiology in the United States (2017-2030)

Table 4 Atopic Dermatitis (AD) Diagnosed and Treatable Cases in the United States (2017-2030)

Table 5 Atopic Dermatitis (AD) Epidemiology in Germany (2017-2030)

Table 6 Atopic Dermatitis (AD) Diagnosed and Treatable Cases in Germany (2017-2030)

Table 7 Atopic Dermatitis (AD) Epidemiology in France (2017-2030)

Table 8 Atopic Dermatitis (AD) Diagnosed and Treatable Cases in France (2017-2030)

Table 9 Atopic Dermatitis (AD) Epidemiology in Italy (2017-2030)

Table 10 Atopic Dermatitis (AD) Diagnosed and Treatable Cases in Italy (2017-2030)

Table 11 Atopic Dermatitis (AD) Epidemiology in Spain (2017-2030)

Table 12 Atopic Dermatitis (AD) Diagnosed and Treatable Cases in Spain (2017-2030)

Table 13 Atopic Dermatitis (AD) Epidemiology in the United Kingdom (2017-2030)

Table 14 Atopic Dermatitis (AD) Diagnosed and Treatable Cases in the United Kingdom (2017-2030)

Table 15 Atopic Dermatitis (AD) Epidemiology in Japan (2017-2030)

Table 16 Atopic Dermatitis (AD) Diagnosed and Treatable Cases in Japan (2017-2030)

Figure 1 Atopic Dermatitis (AD) Epidemiology in 7MM (2017-2030)

Figure 2 Atopic Dermatitis (AD) Diagnosed and Treatable Cases in 7MM (2017-2030)

Figure 3 Atopic Dermatitis (AD) Epidemiology in the United States (2017-2030)

Figure 4 Atopic Dermatitis (AD) Diagnosed and Treatable Cases in the United States (2017-2030)

Figure 5 Atopic Dermatitis (AD) Epidemiology in Germany (2017-2030)

Figure 6 Atopic Dermatitis (AD) Diagnosed and Treatable Cases in Germany (2017-2030)

Figure 7 Atopic Dermatitis (AD) Epidemiology in France (2017-2030)

Figure 8 Atopic Dermatitis (AD) Diagnosed and Treatable Cases in France (2017-2030)

Figure 9 Atopic Dermatitis (AD) Epidemiology in Italy (2017-2030)

Figure 10 Atopic Dermatitis (AD) Diagnosed and Treatable Cases in Italy (2017-2030)

Figure 11 Atopic Dermatitis (AD) Epidemiology in Spain (2017-2030)

Figure 12 Atopic Dermatitis (AD) Diagnosed and Treatable Cases in Spain (2017-2030)

Figure 13 Atopic Dermatitis (AD) Epidemiology in the United Kingdom (2017-2030)

Figure 14 Atopic Dermatitis (AD) Diagnosed and Treatable Cases in the United Kingdom (2017-2030)

Figure 15 Atopic Dermatitis (AD) Epidemiology in Japan (2017-2030)

Figure 16 Atopic Dermatitis (AD) Diagnosed and Treatable Cases in Japan (2017-2030)

*The table of contents is not exhaustive; will be provided in the final report


  • Tags:
  • Atopic Dermatitis (AD) Epidemiology
  • Atopic Dermatitis (AD)
  • Atopic Dermatitis (AD) Pipeline
  • Atopic Dermatitis (AD) Companies
  • Atopic Dermatitis (AD) prevalent p...
  • Atopic Dermatitis (AD) incident po...
  • Atopic Dermatitis (AD) patients di...
  • Atopic Dermatitis (AD) treatment a...

Forward to Friend

Need A Quote